immunomedics inc said filed registration statement with securities and exchange commission for proposed sale 500 000 shares common stock company said will sell 100 000 shares and certain stockholders will sell remaining 400 000 shares proceeds from offering will used for product development basic research staff expansion prepayment debt capital expenditures and working capital company said offering will managed hutton and inc and first boston corp immunomedics said reuter 